azacitidine
not tagged
['aza ']
very proud that the #asco22 presenter is drawing the key distinction between aza +/- idh1i or idh2i trials, and the presence or absence of os benefit being largely driven by adequate or inadequate post-protocol therapy! 
Heme/Onc fellow @SitemanCenter @WUSTLmed | lymphoma/leukemia researcher @LabFehniger